{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:41:07Z","timestamp":1793410867481,"version":"4.5.0"},"reference-count":275,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017410","name":"INCT-INOVAMED","doi-asserted-by":"publisher","award":["465430\/2014\\u20137"],"award-info":[{"award-number":["465430\/2014\\u20137"]}],"id":[{"id":"10.13039\/100017410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["302996\/2019\\u20132"],"award-info":[{"award-number":["302996\/2019\\u20132"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005667","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa e Inova\u00e7\u00e3o do Estado de Santa Catarina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.phrs.2026.108185","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:44:22Z","timestamp":1775231062000},"page":"108185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The role of cannabinoid ligands in neurodegenerative diseases: Emerging anti-inflammatory, immunomodulation and disease-modifying perspectives"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6254-2812","authenticated-orcid":false,"given":"Gabriela Mantovani","family":"Baldasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2330-4862","authenticated-orcid":false,"given":"Rodrigo Sebben","family":"Paes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6182-8513","authenticated-orcid":false,"given":"Artur Graeff","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2144-8080","authenticated-orcid":false,"given":"Sofia Gallo","family":"Salvadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-3886","authenticated-orcid":false,"given":"Christian","family":"Limberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorentina","family":"Roviezzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6938-2161","authenticated-orcid":false,"given":"Rafael Cypriano","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108185_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076635","article-title":"The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study","volume":"8","author":"Degenhardt","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2026.108185_bib2","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/jamapsychiatry.2015.1858","article-title":"Prevalence of marijuana use disorders in the United States Between 2001-2002 and 2012-2013","volume":"72","author":"Hasin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2026.108185_bib3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/jamapsychiatry.2017.0724","article-title":"US adult illicit cannabis use, cannabis use disorder, and medical marijuana Laws: 1991-1992\u20132012-2013","volume":"74","author":"Hasin","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2026.108185_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.drugalcdep.2018.01.022","article-title":"Trends in and correlates of medical marijuana use among adults in the United States","volume":"186","author":"Han","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2026.108185_bib5","article-title":"Alpha\/Beta-Hydrolase Domain-Containing 6: Signaling and Function in the Central Nervous System","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugpo.2017.12.018","article-title":"Consumer agency in cannabis supply - Exploring auto-regulatory documents of the cannabis social clubs in Spain","volume":"54","author":"Belackova","year":"2018","journal-title":"Int J. Drug Policy"},{"key":"10.1016\/j.phrs.2026.108185_bib7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd1495","article-title":"The endocannabinoid system and its therapeutic exploitation","volume":"3","author":"Di Marzo","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108185_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/add.12355","article-title":"Legalizing a market for cannabis for pleasure: Colorado, Washington, Uruguay and beyond","volume":"109","author":"Room","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.phrs.2026.108185_bib9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4088\/JCP.16m10948","article-title":"Cannabis Use and Cannabis Use Disorders Among Youth in the United States, 2002-2014","volume":"78","author":"Han","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2026.108185_bib10","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2016.19706","article-title":"Cannabis use and risk for substance use disorders and mood or anxiety disorders","volume":"317","author":"Hill","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2026.108185_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.drugpo.2017.10.010","article-title":"Interpreting the Czech drug decriminalization: The glass is half full - Response to Cerveny, J., Chomynova, P., Mravcik, V., & van Ours, J.C. (2017). Cannabis decriminalization and the age of onset of cannabis use","volume":"52","author":"Belackova","year":"2018","journal-title":"Int J. Drug Policy"},{"key":"10.1016\/j.phrs.2026.108185_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210215","article-title":"The Mechanisms of the Roles of \u03b1-Synuclein, Amyloid-\u03b2, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics","volume":"24","author":"Noguchi-Shinohara","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00401-017-1709-7","article-title":"Interactions of pathological proteins in neurodegenerative diseases","volume":"134","author":"Spires-Jones","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.phrs.2026.108185_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-019-0329-1","article-title":"Alpha-synuclein structure and Parkinson\u2019s disease - lessons and emerging principles","volume":"14","author":"Meade","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.phrs.2026.108185_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102270","article-title":"Amyloid \u03b2, Tau, and \u03b1-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases","volume":"214","author":"Sengupta","year":"2022","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.phrs.2026.108185_bib16","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.phrs.2026.108185_bib17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/s41591-024-03127-y","article-title":"Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer\u2019s disease","volume":"30","author":"Fortea","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2026.108185_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108185_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-39737-8","article-title":"Integration of plasma and CSF metabolomics with CSF proteomic reveals novel associations between lipid mediators and central nervous system vascular and energy metabolism","volume":"13","author":"Borkowski","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108185_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0163-7258(98)00042-4","article-title":"The role of excitotoxicity in neurodegenerative disease: implications for therapy","volume":"81","author":"Doble","year":"1999","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.phrs.2026.108185_bib22","article-title":"An Effective Method to Identify Shared Pathways and Common Factors among Neurodegenerative Diseases","volume":"10","author":"Li","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2026.108185_bib23","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1038\/s41598-021-84879-2","article-title":"Cannabidiol induces autophagy via ERK1\/2 activation in neural cells","volume":"11","author":"Vrechi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108185_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12640-025-00729-3","article-title":"Cannabidiol-Induced Autophagy Ameliorates Tau Protein Clearance","volume":"43","author":"Vrechi","year":"2025","journal-title":"Neurotox. Res"},{"key":"10.1016\/j.phrs.2026.108185_bib25","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1126\/science.aam9080","article-title":"Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson\u2019s disease","volume":"357","author":"Burbulla","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108185_bib26","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.15252\/embj.201488104","article-title":"A new pathway for mitochondrial quality control: mitochondrial-derived vesicles","volume":"33","author":"Sugiura","year":"2014","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2026.108185_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2013.03.018","article-title":"Mitochondrial diseases of the brain","volume":"63","author":"Chaturvedi","year":"2013","journal-title":"Free Radic. Biol. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib28","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/s41598-024-84479-w","article-title":"Enhancing proteasome activity by NMDAR antagonists explains their therapeutic effect in neurodegenerative and mental diseases","volume":"15","author":"Sahin","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108185_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bcp.2018.08.026","article-title":"\u03949-tetrahydrocannabinol modulates the proteasome system in the brain","volume":"157","author":"Salgado-Mendiald\u00faa","year":"2018","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41418-022-01054-4","article-title":"FAAH served a key membrane-anchoring and stabilizing role for NLRP3 protein independently of the endocannabinoid system","volume":"30","author":"Zhu","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.phrs.2026.108185_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/35040009","article-title":"Apoptosis in neurodegenerative disorders","volume":"1","author":"Mattson","year":"2000","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2026.108185_bib32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.neuro.30.051606.094302","article-title":"Mitochondrial disorders in the nervous system","volume":"31","author":"DiMauro","year":"2008","journal-title":"Annu Rev. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.semcancer.2006.03.005","article-title":"14-3-3 proteins: a historic overview","volume":"16","author":"Aitken","year":"2006","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.phrs.2026.108185_bib34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn1100","article-title":"Targeting programmed cell death in neurodegenerative diseases","volume":"4","author":"Vila","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib35","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12974-024-03326-x","article-title":"Microglia and Immune cells interactions in multiple sclerosis cognitive impairment: a postmortem study","volume":"21","author":"Barros","year":"2024","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2026.108185_bib36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108185_bib37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.phrs.2026.108185_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12974-020-02063-1","article-title":"Chronic exposure to IL-6 induces a desensitized phenotype of the microglia","volume":"18","author":"Recasens","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2026.108185_bib39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1523\/JNEUROSCI.2117-15.2016","article-title":"Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer\u2019s Disease","volume":"36","author":"Lian","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114216","article-title":"Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer\u2019s disease mouse model, as revealed by spatial transcriptomics","volume":"43","author":"Mallach","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2026.108185_bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12974-021-02158-3","article-title":"Crosstalk between astrocytes and microglia results in increased degradation of \u03b1-synuclein and amyloid-\u03b2 aggregates","volume":"18","author":"Rostami","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2026.108185_bib42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12974-024-03221-5","article-title":"Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy","volume":"21","author":"Joers","year":"2024","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2026.108185_bib43","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/glia.24599","article-title":"Endocannabinoids regulate enteric neuron-glia networks and visceral hypersensitivity following inflammation through a glial-dependent mechanism","volume":"72","author":"Morales-Soto","year":"2024","journal-title":"Glia"},{"key":"10.1016\/j.phrs.2026.108185_bib44","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/1574889810999160719105433","article-title":"Endocannabinoid system in neurological disorders","volume":"10","author":"Ranieri","year":"2016","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.phrs.2026.108185_bib45","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11102049","article-title":"Intracellular molecular targets and signaling pathways involved in antioxidative and neuroprotective effects of cannabinoids in neurodegenerative conditions","volume":"11","author":"Tadijan","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.phrs.2026.108185_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115431","article-title":"Neuroprotective and immunomodulatory action of the endocannabinoid system under neuroinflammation","volume":"22","author":"Kasatkina","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2025.107125","article-title":"Demyelination-induced glutamatergic imbalance mediates hippocampal hyperexcitability","volume":"216","author":"Anderson","year":"2025","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib49","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1038\/s41401-021-00853-8","article-title":"CB2 receptor activation inhibits the phagocytic function of microglia through activating ERK\/AKT-Nurr1 signal pathways","volume":"43","author":"Han","year":"2022","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.phrs.2026.108185_bib50","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.neurobiolaging.2012.06.005","article-title":"CB2 receptor and amyloid pathology in frontal cortex of Alzheimer\u2019s disease patients","volume":"34","author":"Solas","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.phrs.2026.108185_bib51","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","article-title":"Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson\u2019s disease","volume":"64","author":"G\u00f3mez-G\u00e1lvez","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2026.108185_bib52","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.108185_bib53","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm1561","article-title":"Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells","volume":"13","author":"Maresz","year":"2007","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib54","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0306-4522(00)00157-3","article-title":"Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington\u2019s disease mice","volume":"98","author":"Denovan-Wright","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2026.108185_bib55","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3233\/JAD-140492","article-title":"R. Type-1 cannabinoid receptor activity during Alzheimer\u2019s disease progression","volume":"42","author":"Manuel","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib56","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00702-003-0033-7","article-title":"Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain","volume":"110","author":"Hurley","year":"2003","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.phrs.2026.108185_bib57","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.tips.2007.02.004","article-title":"The endocannabinoid system in targeting inflammatory neurodegenerative diseases","volume":"28","author":"Centonze","year":"2007","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib58","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1073\/pnas.0306707101","article-title":"P2X7 receptors control 2-arachidonoylglycerol production by microglial cells","volume":"101","author":"Witting","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108185_bib59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1742-2094-2-29","article-title":"Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation","volume":"2","author":"Ehrhart","year":"2005","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2026.108185_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2015.100","article-title":"CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson\u2019s disease","volume":"48","author":"Chung","year":"2016","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.841766","article-title":"Cannabinoid CB2 receptors modulate microglia function and amyloid dynamics in a mouse model of alzheimer\u2019s disease","volume":"13","author":"Ruiz de Mart\u00edn Esteban","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib62","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41593-025-01891-9","article-title":"Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations","volume":"28","author":"Dudek","year":"2025","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib63","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bbi.2018.12.013","article-title":"The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia","volume":"77","author":"Mecha","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.phrs.2026.108185_bib64","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/glia.20756","article-title":"2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells","volume":"57","author":"Kreutz","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.phrs.2026.108185_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.387","article-title":"The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG","volume":"4","author":"Valdeolivas","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib66","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3233\/JAD-142349","article-title":"Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer\u2019s disease patients as a potential protective mechanism against neurodegenerative decline","volume":"46","author":"Altamura","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib67","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.nbd.2018.06.019","article-title":"The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing\/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia","volume":"118","author":"Rojo-Bustamante","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib68","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41593-025-02148-1","article-title":"Distinct endocannabinoids specifically signal to astrocytes or neurons in the adult mouse hippocampus","volume":"29","author":"Noriega-Prieto","year":"2026","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib69","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12031-010-9472-4","article-title":"A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity","volume":"43","author":"Naidoo","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib70","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/sj.cdd.4401442","article-title":"Anandamide-induced cell death in primary neuronal cultures: role of calpain and caspase pathways","volume":"11","author":"Movsesyan","year":"2004","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.phrs.2026.108185_bib71","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.neurobiolaging.2011.03.012","article-title":"An amyloid \u03b242-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer\u2019s disease","volume":"33","author":"Jung","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.phrs.2026.108185_bib72","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/mds.28186","article-title":"High glucosylceramides and low anandamide contribute to sensory loss and pain in parkinson\u2019s disease","volume":"35","author":"Klatt-Schreiner","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.phrs.2026.108185_bib73","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/jnnp.2007.139071","article-title":"Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis","volume":"79","author":"Di Filippo","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.phrs.2026.108185_bib74","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuron.2005.11.027","article-title":"The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells","volume":"49","author":"Eljaschewitsch","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2026.108185_bib75","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/130639","article-title":"Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures","volume":"2015","author":"Malek","year":"2015","journal-title":"Neural Plast."},{"key":"10.1016\/j.phrs.2026.108185_bib76","doi-asserted-by":"crossref","first-page":"20869","DOI":"10.1074\/jbc.M110813200","article-title":"Astrocytes in culture produce anandamide and other acylethanolamides","volume":"277","author":"Walter","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108185_bib77","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2015.04.005","article-title":"Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies","volume":"79","author":"V\u00e1zquez","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174398","article-title":"Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases","volume":"909","author":"Hashiesh","year":"2021","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.702675","article-title":"Pharmacological properties, therapeutic potential and molecular mechanisms of JWH133, a CB2 Receptor-Selective Agonist","volume":"12","author":"Hashiesh","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000362689","article-title":"\u03b2-Caryophyllene ameliorates the Alzheimer-like phenotype in APP\/PS1 Mice through CB2 receptor activation and the PPAR\u03b3 pathway","volume":"94","author":"Cheng","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.phrs.2026.108185_bib81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.lfs.2018.12.059","article-title":"The protective effects of \u03b2-caryophyllene on LPS-induced primary microglia M1\/M2 imbalance: a mechanistic evaluation","volume":"219","author":"Askari","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104646","article-title":"Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia","volume":"134","author":"Rentsch","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib83","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70099","article-title":"CB1 Receptor activation provides neuroprotection in an animal model of glutamate-induced excitotoxicity through a reduction of NOX-2 Activity and Oxidative Stress","volume":"30","author":"Mart\u00ednez-Torres","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.phrs.2026.108185_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75962-5","article-title":"Extracellular glutamate is not modulated by cannabinoid receptor activity","volume":"14","author":"Chiu","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108185_bib85","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0081-19.2020","article-title":"Cannabinoid signaling recruits astrocytes to modulate presynaptic function in the suprachiasmatic nucleus","volume":"7","author":"Hablitz","year":"2020","journal-title":"ENeuro"},{"key":"10.1016\/j.phrs.2026.108185_bib86","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/1871527311312010012","article-title":"Physiological role of peroxisome proliferator-activated receptors type \u03b1 on dopamine systems","volume":"12","author":"Melis","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.phrs.2026.108185_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2025.1571428","article-title":"Chronic palmitoylethanolamide administration via slow-release subcutaneous pellets promotes neuroprotection and mitigates neuroinflammation in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"19","author":"Tortolani","year":"2025","journal-title":"Front Cell Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib88","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.phrs.2016.09.004","article-title":"Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence","volume":"113","author":"Avagliano","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108185_bib89","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bjp.0704466","article-title":"Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat","volume":"135","author":"Conti","year":"2002","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib90","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0014-2999(96)00015-5","article-title":"N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation","volume":"300","author":"Mazzari","year":"1996","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib91","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1098\/rstb.2011.0391","article-title":"Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide","volume":"367","author":"Skaper","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib92","article-title":"n.d","year":"2025","journal-title":"World Alzheimer Rep."},{"key":"10.1016\/j.phrs.2026.108185_bib93","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s004060050027","article-title":"The case described by Alois Alzheimer in 1911","volume":"248","author":"M\u00f6ller","year":"1998","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jocn.2015.12.032","article-title":"Professor Alois Alzheimer (1864-1915): Lest we forget","volume":"31","author":"Toodayan","year":"2016","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib95","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-\u03b2 Pathway in Alzheimer\u2019s Disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2026.108185_bib96","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX(N) classification for use across the Alzheimer disease continuum","volume":"17","author":"Hampel","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib97","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","article-title":"Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease","volume":"12","author":"Hardy","year":"1991","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101503","article-title":"Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer\u2019s disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies","volume":"72","author":"Song","year":"2021","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.phrs.2026.108185_bib99","doi-asserted-by":"crossref","first-page":"8189","DOI":"10.1007\/s00210-024-03188-3","article-title":"Oxidative stress-mediated neuroinflammation in Alzheimer\u2019s disease","volume":"397","author":"Firdous","year":"2024","journal-title":"Naunyn Schmiede Arch. Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib100","article-title":"Unravelling the Alzheimer\u2019s pathogenesis: Molecular and cellular pathways to neurodegeneration and therapeutic targets","volume":"272","author":"Chauhan","year":"2025","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.phrs.2026.108185_bib101","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib102","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1098\/rstb.1999.0471","article-title":"Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging","volume":"354","author":"Magistretti","year":"1999","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib103","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1101\/lm.1893710","article-title":"Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat","volume":"17","author":"Goonawardena","year":"2010","journal-title":"Learn Mem."},{"key":"10.1016\/j.phrs.2026.108185_bib104","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer\u2019s disease: Targeting the Cholinergic System","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.phrs.2026.108185_bib105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrn2168","article-title":"Intracellular amyloid-beta in Alzheimer\u2019s disease","volume":"8","author":"LaFerla","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib106","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.brainresbull.2021.06.022","article-title":"The role of endocannabinoid pathway in the neuropathology of Alzheimer\u2019s disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer\u2019s disease?","volume":"174","author":"Bajaj","year":"2021","journal-title":"Brain Res Bull."},{"key":"10.1016\/j.phrs.2026.108185_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109545","article-title":"Crosstalk between the M1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer\u2019s disease?","volume":"70","author":"Thompson","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.phrs.2026.108185_bib108","article-title":"Alzheimer\u2019s disease and memantine effects on NMDA-receptor blockade: non-invasive in vivo insights from magnetoencephalography","author":"Lanskey","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2026.108185_bib109","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","article-title":"Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse","volume":"53","author":"Parsons","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2026.108185_bib110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108185_bib111","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib112","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamainternmed.2021.4622","article-title":"The accelerated approval of aducanumab for treatment of patients with alzheimer disease","volume":"181","author":"Steinbrook","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.phrs.2026.108185_bib113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib114","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2026.108185_bib116","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00702-010-0433-4","article-title":"The role of microglia in amyloid clearance from the AD brain","volume":"117","author":"Lee","year":"2010","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.phrs.2026.108185_bib117","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","article-title":"Differential roles of M1 and M2 microglia in neurodegenerative diseases","volume":"53","author":"Tang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2026.108185_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.888989","article-title":"The role of microglia in alzheimer\u2019s disease from the perspective of immune inflammation and iron metabolism","volume":"14","author":"Long","year":"2022","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib119","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00401-021-02372-6","article-title":"Diverse human astrocyte and microglial transcriptional responses to Alzheimer\u2019s pathology","volume":"143","author":"Smith","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.phrs.2026.108185_bib120","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.cell.2018.05.003","article-title":"Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration","volume":"173","author":"Deczkowska","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108185_bib121","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fnins.2016.00243","article-title":"CB2 Cannabinoid receptor as potential target against Alzheimer\u2019s disease","volume":"10","author":"Aso","year":"2016","journal-title":"Front Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib122","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12974-018-1174-9","article-title":"Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer\u2019s disease","volume":"15","author":"L\u00f3pez","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2026.108185_bib123","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"ML. Prevention of Alzheimer\u2019s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ram\u00edrez","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib124","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/s41419-024-07249-6","article-title":"Microglial cannabinoid receptor type II stimulation improves cognitive impairment and neuroinflammation in Alzheimer\u2019s disease mice by controlling astrocyte activation","volume":"15","author":"Sobue","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/cells8050491","article-title":"Anti-Inflammatory Effects by Pharmacological Inhibition or Knockdown of Fatty Acid Amide Hydrolase in BV2 Microglial Cells","volume":"8","author":"Tanaka","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2026.108185_bib126","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1021\/acsbiomaterials.5c00465","article-title":"Engineered PLGA Nanoparticles for Brain-Targeted Codelivery of Cannabidiol and pApoE2 through the Intranasal Route for the Treatment of Alzheimer\u2019s Disease","volume":"11","author":"Mahanta","year":"2025","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.phrs.2026.108185_bib127","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1007\/s12035-021-02400-2","article-title":"Inhibition of 2-arachidonoylglycerol metabolism alleviates neuropathology and improves cognitive function in a tau mouse model of Alzheimer\u2019s Disease","volume":"58","author":"Hashem","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2026.108185_bib128","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1016\/j.neurobiolaging.2015.08.003","article-title":"Endocannabinoid regulation of amyloid-induced neuroinflammation","volume":"36","author":"V\u00e1zquez","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.phrs.2026.108185_bib129","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3233\/JAD-2012-120982","article-title":"Evidence for early cognitive impairment related to frontal cortex in the 5XFAD mouse model of Alzheimer\u2019s disease","volume":"33","author":"Girard","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12974-021-02276-y","article-title":"Potentiation of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer\u2019s disease","volume":"18","author":"Ruiz-P\u00e9rez","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2026.108185_bib131","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nm.4311","article-title":"A chronic low dose of \u03949-tetrahydrocannabinol (THC) restores cognitive function in old mice","volume":"23","author":"Bilkei-Gorzo","year":"2017","journal-title":"Nat. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25071567","article-title":"Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant","volume":"25","author":"Gon\u00e7alves","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2026.108185_bib133","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4926815","article-title":"Amelioration of Scopolamine-Induced Learning and Memory Impairment by \u03b1-Pinene in C57BL\/6 Mice","volume":"2017","author":"Lee","year":"2017","journal-title":"Evid. Based Complement Altern. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib134","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8887716","article-title":"Linalool Alleviates A\u03b242-Induced Neurodegeneration via Suppressing ROS Production and Inflammation in Fly and Rat Models of Alzheimer\u2019s Disease","volume":"2021","author":"Yuan","year":"2021","journal-title":"Oxid. Med Cell Longev."},{"key":"10.1016\/j.phrs.2026.108185_bib135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lfs.2017.02.010","article-title":"Protective effects of linalool against amyloid beta-induced cognitive deficits and damages in mice","volume":"174","author":"Xu","year":"2017","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/biom11040502","article-title":"Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes\/Macrophages from Alzheimer\u2019s Disease Patients","volume":"11","author":"Chiurchi\u00f9","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2026.108185_bib137","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/can.2022.0151","article-title":"Endocannabinoid system biomarkers in alzheimer\u2019s disease","volume":"8","author":"Ferreira","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.phrs.2026.108185_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1240800","article-title":"The dual role of cannabidiol on monocyte-derived dendritic cell differentiation and maturation","volume":"14","author":"P\u00e9nzes","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2026.108185_bib139","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13256-022-03457-w","article-title":"Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer\u2019s disease symptoms: a case report","volume":"16","author":"Ruver-Martins","year":"2022","journal-title":"J. Med Case Rep."},{"key":"10.1016\/j.phrs.2026.108185_bib140","doi-asserted-by":"crossref","DOI":"10.1177\/13872877251389608","article-title":"A randomized clinical trial of low-dose cannabis extract in Alzheimer\u2019s disease","author":"Cury","year":"2025","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib141","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMra2401857","article-title":"2. Parkinson\u2019s Disease","volume":"391","author":"Tanner","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib142","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Dementia Collaborators","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib143","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"1. The epidemiology of Parkinson\u2019s disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108185_bib144","first-page":"S3","article-title":"The emerging evidence of the parkinson pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib145","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamaneurol.2023.1168","article-title":"Risk of parkinson disease among service members at marine corps base camp lejeune","volume":"80","author":"Goldman","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib146","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010233","article-title":"Dysregulated interorganellar crosstalk of mitochondria in the pathogenesis of parkinson\u2019s disease","volume":"9","author":"Sironi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2026.108185_bib147","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"4. Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108185_bib148","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"5. The pathogenesis of Parkinson\u2019s disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108185_bib149","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.900338","article-title":"Inter-organellar Communication in Parkinson\u2019s and Alzheimer\u2019s Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites","volume":"16","author":"Vrijsen","year":"2022","journal-title":"Front Neurosci."},{"issue":"7","key":"10.1016\/j.phrs.2026.108185_bib150","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson\u2019s disease and parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am. J. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib151","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108185_bib152","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","article-title":"Parkinson\u2019s disease","volume":"363","author":"Samii","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108185_bib153","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071687","article-title":"A. Inflammation in parkinson\u2019s disease: mechanisms and therapeutic implications","volume":"9","author":"Pajares","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2026.108185_bib154","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4784268","article-title":"Linking neuroinflammation and neurodegeneration in parkinson\u2019s disease","volume":"2018","author":"Gelders","year":"2018","journal-title":"J. Immunol. Res"},{"key":"10.1016\/j.phrs.2026.108185_bib155","doi-asserted-by":"crossref","DOI":"10.3390\/cells12071012","article-title":"Microglia mediated neuroinflammation in parkinson\u2019s disease","volume":"12","author":"Isik","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2026.108185_bib156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","article-title":"The blood-brain barrier in systemic inflammation","volume":"60","author":"Varatharaj","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.phrs.2026.108185_bib157","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2026.108185_bib158","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228421","article-title":"Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson\u2019s Disease","volume":"21","author":"Marogianni","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib159","article-title":"Role of Astrocytes in Parkinson\u2019s Disease Associated with Genetic Mutations and Neurotoxicants","volume":"12","author":"Kim","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2026.108185_bib160","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.celrep.2017.12.092","article-title":"Cellular senescence is induced by the environmental neurotoxin paraquat and contributes to neuropathology linked to parkinson\u2019s disease","volume":"22","author":"Chinta","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2026.108185_bib161","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.redox.2017.01.006","article-title":"Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases","volume":"11","author":"Pajares","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.phrs.2026.108185_bib162","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123824","article-title":"The role of NADPH oxidases and oxidative stress in neurodegenerative disorders","volume":"19","author":"Tarafdar","year":"2018","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134296","article-title":"Oxidative stress and Parkinson\u2019s disease: conflict of oxidant-antioxidant systems","volume":"709","author":"Hemmati-Dinarvand","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2026.108185_bib164","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fnagi.2015.00124","article-title":"Microglial cell dysregulation in brain aging and neurodegeneration","volume":"7","author":"von Bernhardi","year":"2015","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib165","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(05)70285-4","article-title":"The diagnosis of Parkinson\u2019s disease","volume":"5","author":"Tolosa","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib166","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.595635","article-title":"Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in parkinson\u2019s disease","volume":"11","author":"Patricio","year":"2020","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib167","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/jnc.14098","article-title":"Endocannabinoid system in neurodegenerative disorders","volume":"142","author":"Basavarajappa","year":"2017","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2026.108185_bib168","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s13311-018-0603-x","article-title":"Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson\u2019s Disease","volume":"15","author":"Navarrete","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2026.108185_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2011.02.009","article-title":"Regional changes in type 1 cannabinoid receptor availability in Parkinson\u2019s disease in vivo","volume":"33","author":"Van Laere","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.phrs.2026.108185_bib170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib171","article-title":"Endocannabinoid modulation in neurodegenerative diseases: in pursuit of certainty","volume":"11","author":"Vasincu","year":"2022","journal-title":"Biol. (Basel)"},{"key":"10.1016\/j.phrs.2026.108185_bib172","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1523\/JNEUROSCI.23-16-06470.2003","article-title":"Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia","volume":"23","author":"Molina-Holgado","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib173","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12974-018-1060-5","article-title":"Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson\u2019s disease: possible involvement of different binding sites at the PPAR\u03b3 receptor","volume":"15","author":"Garc\u00eda","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2026.108185_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2025.111456","article-title":"Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems","volume":"141","author":"Nascimento","year":"2025","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2026.108185_bib175","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3940(99)00762-4","article-title":"Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats","volume":"276","author":"Zeng","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2026.108185_bib176","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-018-0996-1","article-title":"Medical use of cannabinoids","volume":"78","author":"Fraguas-S\u00e1nchez","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108185_bib177","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/ana.20462","article-title":"High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson\u2019s disease patients","volume":"57","author":"Pisani","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib178","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1073\/pnas.1600013113","article-title":"Individual differences in frontolimbic circuitry and anxiety emerge with adolescent changes in endocannabinoid signaling across species","volume":"113","author":"Gee","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108185_bib179","first-page":"143","article-title":"Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage. Neurologia","volume":"34","author":"Viveros-Paredes","year":"2019"},{"key":"10.1016\/j.phrs.2026.108185_bib180","doi-asserted-by":"crossref","first-page":"12984","DOI":"10.1007\/s12035-025-05104-z","article-title":"The inhibition of fatty acid amide hydrolase-4 affords neuroprotection in a toxic model induced by 6-hydroxydopamine in caenorhabditis elegans nematodes","volume":"62","author":"Estrada-Valencia","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2026.108185_bib181","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson\u2019s disease","volume":"19","author":"Lastres-Becker","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib182","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fnins.2016.00321","article-title":"Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson\u2019s Disease","volume":"10","author":"Javed","year":"2016","journal-title":"Front Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib183","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson\u2019s disease: importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Garc\u00eda-Arencibia","year":"2007","journal-title":"Brain Res"},{"key":"10.1016\/j.phrs.2026.108185_bib184","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/mds.10289","article-title":"Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease","volume":"17","author":"Fox","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.phrs.2026.108185_bib185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.expneurol.2007.07.021","article-title":"Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson\u2019s disease: role of CB(1) and TRPV1 receptors","volume":"208","author":"Morgese","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib186","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/FBP.0000000000000004","article-title":"The combination of oral L-DOPA\/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson\u2019s disease and L-DOPA-induced dyskinesia","volume":"24","author":"Guti\u00e9rrez-Valdez","year":"2013","journal-title":"Behav. Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib187","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.procbio.2021.08.025","article-title":"Cannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactions\u2014A review","volume":"111","author":"Pugazhendhi","year":"2021","journal-title":"Process Biochem."},{"key":"10.1016\/j.phrs.2026.108185_bib188","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNF.0000000000000016","article-title":"Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study","volume":"37","author":"Lotan","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.phrs.2026.108185_bib189","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.phrs.2026.108185_bib190","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2026.108185_bib191","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.25864","article-title":"Non-Motor Symptoms in Parkinson\u2019s Disease are Reduced by Nabilone","volume":"88","author":"Peball","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib192","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00702-019-02021-z","article-title":"Nabilone for non-motor symptoms of Parkinson\u2019s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)","volume":"126","author":"Peball","year":"2019","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.phrs.2026.108185_bib193","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s43450-025-00675-3","article-title":"A High-Dose THC Cannabis Oil Improves Motor and Non-motor Symptoms in Parkinson\u2019s Disease: A Case Report","volume":"35","author":"Dall\u2019soto","year":"2025","journal-title":"Rev. Bras. De. Farmacogn."},{"key":"10.1016\/j.phrs.2026.108185_bib194","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/jcpt.12179","article-title":"Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: a case series","volume":"39","author":"Chagas","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.phrs.2026.108185_bib195","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.phrs.2026.108185_bib196","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.phrs.2026.108185_bib197","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin Expression in Patients with Huntington\u2019s Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib198","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib199","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-444-63233-3.00017-8","article-title":"Ghosh R, Tabrizi SJ. Huntington disease","volume":"147","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib200","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108185_bib201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-71779-1_1","article-title":"Clinical features of huntington\u2019s disease","volume":"1049","author":"Ghosh","year":"2018","journal-title":"Adv. Exp. Med Biol."},{"key":"10.1016\/j.phrs.2026.108185_bib202","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","article-title":"Psychopathology in verified Huntington\u2019s disease gene carriers","volume":"19","author":"van Duijn","year":"2007","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib203","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033118","article-title":"Clinical neurology and epidemiology of the major neurodegenerative diseases","volume":"10","author":"Erkkinen","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.phrs.2026.108185_bib204","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib205","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3233\/JHD-190372","article-title":"The role of hypothalamic pathology for non-motor features of Huntington\u2019s Disease","volume":"8","author":"Cheong","year":"2019","journal-title":"J. Huntingt. Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105147","article-title":"Mitophagy in Huntington\u2019s disease","volume":"149","author":"\u0160onsk\u00fd","year":"2021","journal-title":"Neurochem. Int"},{"key":"10.1016\/j.phrs.2026.108185_bib207","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bj\u00f6rkqvist","year":"2008","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.phrs.2026.108185_bib208","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington\u2019s disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.108185_bib209","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.semcdb.2019.05.004","article-title":"Microglia-mediated neuroinflammation in neurodegenerative diseases","volume":"94","author":"Subhramanyam","year":"2019","journal-title":"Semin Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2026.108185_bib210","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cels.2018.05.010","article-title":"High-Throughput Functional Analysis Distinguishes Pathogenic, Nonpathogenic, and Compensatory Transcriptional Changes in Neurodegeneration","volume":"7","author":"Al-Ramahi","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.phrs.2026.108185_bib211","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2174\/1570159X18666200522201123","article-title":"Therapeutic and mechanistic effects of curcumin in huntington\u2019s disease","volume":"19","author":"Labanca","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.phrs.2026.108185_bib212","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13311-014-0304-z","article-title":"Neuroprotective properties of cannabigerol in Huntington\u2019s disease: studies in R6\/2 mice and 3-nitropropionate-lesioned mice","volume":"12","author":"Valdeolivas","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2026.108185_bib213","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1111\/bph.15185","article-title":"O\u2019Sullivan SE. A systematic review of minor phytocannabinoids with promising neuroprotective potential","volume":"177","author":"Stone","year":"2020","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib214","doi-asserted-by":"crossref","DOI":"10.1038\/srep29789","article-title":"VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington\u2019s disease","volume":"6","author":"D\u00edaz-Alonso","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108185_bib215","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s11481-012-9399-3","article-title":"A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis","volume":"7","author":"Granja","year":"2012","journal-title":"J. Neuroimmune Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib216","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12640-020-00277-y","article-title":"A Comparative in vitro study of the neuroprotective effect induced by cannabidiol, cannabigerol, and their respective acid forms: relevance of the 5-HT1A Receptors","volume":"39","author":"Echeverry","year":"2021","journal-title":"Neurotox. Res"},{"key":"10.1016\/j.phrs.2026.108185_bib217","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/mol.115.101980","article-title":"Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of huntington disease","volume":"89","author":"Laprairie","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2026.108185_bib218","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18040684","article-title":"Effects of a sativex-like combination of phytocannabinoids on disease progression in R6\/2 Mice, an experimental model of Huntington\u2019s Disease","volume":"18","author":"Valdeolivas","year":"2017","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2019.03.033","article-title":"Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington\u2019s disease in the R6\/2 mouse model","volume":"151","author":"Laprairie","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2026.108185_bib220","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.nbd.2011.03.006","article-title":"Worsening of Huntington disease phenotype in CB1 receptor knockout mice","volume":"42","author":"Mievis","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib221","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.nbd.2014.08.009","article-title":"Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice","volume":"71","author":"Naydenov","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib222","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neuropharm.2013.04.006","article-title":"Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington\u2019s disease","volume":"72","author":"Laprairie","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2026.108185_bib223","doi-asserted-by":"crossref","DOI":"10.3389\/fncom.2022.903947","article-title":"Cannabinoid signaling and risk in Huntington\u2019s disease","volume":"16","author":"Humble","year":"2022","journal-title":"Front Comput. Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib224","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fnsyn.2019.00014","article-title":"Major contribution of somatostatin-expressing interneurons and cannabinoid receptors to increased gaba synaptic activity in the striatum of Huntington\u2019s Disease Mice","volume":"11","author":"Holley","year":"2019","journal-title":"Front Synaptic Neurosci."},{"key":"10.1016\/j.phrs.2026.108185_bib225","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40035-025-00500-w","article-title":"Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington\u2019s disease models","volume":"14","author":"Di Franco","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.phrs.2026.108185_bib226","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neuropharm.2019.03.027","article-title":"Astroglial monoacylglycerol lipase controls mutant huntingtin-induced damage of striatal neurons","volume":"150","author":"Ruiz-Calvo","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2026.108185_bib227","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neuint.2018.04.015","article-title":"Huntington\u2019s disease pattern of transcriptional dysregulation in the absence of mutant huntingtin is produced by knockout of neuronal GLT-1","volume":"123","author":"Laprairie","year":"2019","journal-title":"Neurochem. Int"},{"key":"10.1016\/j.phrs.2026.108185_bib228","article-title":"Positive allosteric modulation of CB1 and CB2 cannabinoid receptors enhances the neuroprotective activity of a dual CB1R\/CB2R orthosteric agonist","volume":"10","author":"Polini","year":"2020","journal-title":"Life (Basel)"},{"key":"10.1016\/j.phrs.2026.108185_bib229","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116592","article-title":"Novel neuroprotective 5,6-dihydropyrido[2\u2019,1\u2019:2,3]imidazo[4,5-c]quinoline derivatives acting through cholinesterase inhibition and CB2 signaling modulation","volume":"276","author":"Jena","year":"2024","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.phrs.2026.108185_bib230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JHD-170283","article-title":"Cannabinoids for treatment of dystonia in huntington\u2019s disease","volume":"7","author":"Saft","year":"2018","journal-title":"J. Huntingt. Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib231","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0306-4522(03)00595-5","article-title":"Delayed onset of Huntington\u2019s disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors","volume":"123","author":"Glass","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2026.108185_bib232","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/brain\/awh641","article-title":"Cortical demyelination and diffuse white matter injury in multiple sclerosis","volume":"128","author":"Kutzelnigg","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.108185_bib233","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.phrs.2026.108185_bib234","doi-asserted-by":"crossref","first-page":"v3","DOI":"10.1007\/s00415-005-5002-7","article-title":"The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage","volume":"252","author":"Br\u00fcck","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib235","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib236","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1084\/jem.184.6.2361","article-title":"Multiple sclerosis: Fas signaling in oligodendrocyte cell death","volume":"184","author":"D\u2019Souza","year":"1996","journal-title":"J. Exp. Med"},{"issue":"Pt 3","key":"10.1016\/j.phrs.2026.108185_bib237","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/brain\/120.3.393","article-title":"Axonal damage in acute multiple sclerosis lesions","volume":"120","author":"Ferguson","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.108185_bib238","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2026.108185_bib239","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108185_bib240","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S1474-4422(06)70581-6","article-title":"Sex ratio of multiple sclerosis in Canada: a longitudinal study","volume":"5","author":"Orton","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib241","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/bmj.3.5777.725","article-title":"On the risk of multiple sclerosis according to age at immigration to South Africa","volume":"3","author":"Dean","year":"1971","journal-title":"Br. Med J."},{"issue":"Pt 2","key":"10.1016\/j.phrs.2026.108185_bib242","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/brain\/119.2.449","article-title":"Age-adjusted recurrence risks for relatives of patients with multiple sclerosis","volume":"119","author":"Robertson","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.108185_bib243","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ng0896-464","article-title":"A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22","volume":"13","author":"Sawcer","year":"1996","journal-title":"Nat. Genet"},{"key":"10.1016\/j.phrs.2026.108185_bib244","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1086\/426459","article-title":"A second-generation genomic screen for multiple sclerosis","volume":"75","author":"Kenealy","year":"2004","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.phrs.2026.108185_bib245","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-026-05780-5","article-title":"Neuroprotective role of cannabinoid CB1 and GPR55 receptors in a cell model of multiple sclerosis","volume":"63","author":"Mart\u00ednez-Pinilla","year":"2026","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2026.108185_bib246","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-026-03708-3","article-title":"Astrocyte CB1 receptors drive blood-brain barrier disruption in central nervous system inflammatory disease","volume":"23","author":"Colomer","year":"2026","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2026.108185_bib247","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.drudis.2019.05.023","article-title":"Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?","volume":"24","author":"Gon\u00e7alves","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2026.108185_bib248","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.4103\/1673-5374.301011","article-title":"A closer look at cannabimimetic terpenes, polyphenols, and flavonoids: a promising road forward","volume":"16","author":"Cavalli","year":"2021","journal-title":"Neural Regen. Res"},{"key":"10.1016\/j.phrs.2026.108185_bib249","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200219","article-title":"Metabolomics of Multiple sclerosis Lesions Demonstrates Lipid Changes Linked to Alterations in Transcriptomics-Based Cellular Profiles","volume":"11","author":"Ladakis","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.phrs.2026.108185_bib250","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70285","article-title":"The serum lipid profile of relapsing multiple sclerosis differs reproducibly from healthy controls","volume":"169","author":"Shi","year":"2025","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2026.108185_bib251","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s40478-024-01864-2","article-title":"Comparative targeted lipidomics between serum and cerebrospinal fluid of multiple sclerosis patients shows sex and age-specific differences of endocannabinoids and glucocorticoids","volume":"12","author":"Meier","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.phrs.2026.108185_bib252","doi-asserted-by":"crossref","DOI":"10.1016\/j.dib.2025.111948","article-title":"Targeted lipidomics dataset of central nervous system and plasma from mice with experimental autoimmune encephalomyelitis","volume":"62","author":"L\u00f6tsch","year":"2025","journal-title":"Data Brief."},{"key":"10.1016\/j.phrs.2026.108185_bib253","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084176","article-title":"Heteromers formed by GPR55 and either cannabinoid CB1 or CB2 receptors are upregulated in the prefrontal cortex of multiple sclerosis patients","volume":"25","author":"Men\u00e9ndez-P\u00e9rez","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib254","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109940","article-title":"Pharmacological blockade of 2-AG degradation ameliorates clinical, neuroinflammatory and synaptic alterations in experimental autoimmune encephalomyelitis","volume":"252","author":"Guadalupi","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2026.108185_bib255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112858","article-title":"The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis","volume":"208","author":"Arena","year":"2020","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.phrs.2026.108185_bib256","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104994","article-title":"Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis","volume":"143","author":"Navarrete","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108185_bib257","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020376","article-title":"Therapeutic potential of phytocannabinoid cannabigerol for multiple sclerosis: modulation of microglial activation in vitro and in vivo","volume":"13","author":"Fleisher-Berkovich","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2026.108185_bib258","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s42238-024-00232-0","article-title":"Selected cannabis cultivars modulate glial activation: in vitro and in vivo studies","volume":"6","author":"Fleisher-Berkovich","year":"2024","journal-title":"J. Cannabis Res"},{"key":"10.1016\/j.phrs.2026.108185_bib259","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27061763","article-title":"Botanically-Derived \u03949-Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple sclerosis","volume":"27","author":"Fitzpatrick","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2026.108185_bib260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18040691","article-title":"-)-\u03b2-Caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor paralysis and neuroinflammation in a murine model of multiple sclerosis","volume":"18","author":"Alberti","year":"2017","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib261","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000549178","article-title":"UK medical cannabis registry: an updated analysis of cannabis-based medicinal products for multiple sclerosis","volume":"8","author":"Shah","year":"2025","journal-title":"Med Cannabis Cannabinoids"},{"key":"10.1016\/j.phrs.2026.108185_bib262","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1440678","article-title":"Efficacy of cannabinoids compared to the current standard treatments on symptom relief in persons with multiple sclerosis (CANSEP trial): study protocol for a randomized clinical trial","volume":"15","author":"Zertal","year":"2024","journal-title":"Front Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib263","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clinthera.2025.07.009","article-title":"Assessing the Role of Cannabis in Managing Spasticity in Multiple sclerosis: A Systematic Review and Meta-Analysis","volume":"48","author":"AlHabil","year":"2026","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2026.108185_bib264","article-title":"Daily temporal associations between use of psychoactive substances and fatigue, pain, stress, and depressive symptoms in people with multiple sclerosis","author":"Kim","year":"2026","journal-title":"Arch. Phys. Med Rehabil."},{"key":"10.1016\/j.phrs.2026.108185_bib265","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.phrs.2026.108185_bib266","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0773.1977.tb02120.x","article-title":"Penetration of delta-9-tetrahydrocannabinol and 11-OH-delta-9-tetrahydrocannabinol through the blood-brain barrier","volume":"41","author":"Schou","year":"1977","journal-title":"Acta Pharm. Toxicol. (Copenh)"},{"key":"10.1016\/j.phrs.2026.108185_bib267","article-title":"Strategies to improve cannabidiol bioavailability and drug delivery","volume":"17","author":"O\u2019Sullivan","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.phrs.2026.108185_bib268","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s42238-025-00308-5","article-title":"Quantitation of Cannabidiol (CBD) in brain regions and plasma following intranasal administration of a CBD nanoformulation","volume":"7","author":"Upadhyay","year":"2025","journal-title":"J. Cannabis Res"},{"key":"10.1016\/j.phrs.2026.108185_bib269","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0305868","article-title":"Cannabinoid receptor 1 positive allosteric modulator ZCZ011 shows differential effects on behavior and the endocannabinoid system in HIV-1 Tat transgenic female and male mice","volume":"19","author":"Yadav-Samudrala","year":"2024","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2026.108185_bib270","article-title":"The Cannabinoids, CBDA and THCA, Rescue Memory Deficits and Reduce Amyloid-Beta and Tau Pathology in an Alzheimer\u2019s Disease-like Mouse Model","volume":"24","author":"Kim","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib271","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262411905","article-title":"Type-1 Cannabinoid Receptor Promiscuous Coupling: Computational Insights into Receptor-G Protein Interaction Dynamics","volume":"26","author":"Berghella","year":"2025","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108185_bib272","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109027","article-title":"Multimodal profiling of Pepcan-CB1 receptor structure-activity relationships: integrating molecular dynamics simulations, biological profiling, and the deep learning model MuMoPepcan","volume":"165","author":"Man","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2026.108185_bib273","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease","volume":"263","author":"L\u00f3pez-Send\u00f3n Moreno","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib274","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1474-4422(18)30406-X","article-title":"Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"18","author":"Riva","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2026.108185_bib275","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jagp.2025.10.011","article-title":"A randomized controlled trial of the safety and efficacy of dronabinol for agitation in Alzheimer\u2019s disease","volume":"34","author":"Rosenberg","year":"2026","journal-title":"Am. J. Geriatr. Psychiatry"}],"updated-by":[{"DOI":"10.1016\/j.phrs.2026.108206","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000}},{"DOI":"10.1016\/j.phrs.2026.108206","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000}}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:44:48Z","timestamp":1778795088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":275,"alternative-id":["S1043661826001003"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108185","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of cannabinoid ligands in neurodegenerative diseases: Emerging anti-inflammatory, immunomodulation and disease-modifying perspectives","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108185"}}